PUBLICATIONS

AAHI pioneers immune-enhancing platforms to provide potent, durable, broadly effective, and efficient vaccines and immunotherapies that are accessible to those who most need them.

Publications

FILTER BY TOPIC

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults

03/06/2023

Nature Communications

Semi-synthetic terpenoids with differential adjuvant properties as sustainable replacements for shark squalene in vaccine emulsions

02/16/2023

npj Vaccines

A prospective study of clinical outcomes of HIV-associated and HIV-negative Kaposi sarcoma in Uganda

01/01/2023

AIDS

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines

12/02/2022

Molecular Therapy, Nucleic Acids

Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later

12/01/2022

Science Translational Medicine

Formulated Phospholipids as Non-Canonical TLR4 Agonists

11/22/2022

Pharmaceutics

Vaccine Development: From Concept to Clinic, Chapter 10: Vaccine Adjuvants: Mechanisms of Action

11/09/2022

Royal Society of Chemistry

Lyophilization process engineering and thermostability of ID93 + GLA-SE, a single-vial adjuvanted subunit tuberculosis vaccine candidate for use in clinical studies

11/08/2022

Frontiers in Drug Delivery

A self-amplifying RNA vaccine against COVID-19 with long-term room-termperature stability

11/02/2022

npj Vaccines

A novel asexual blood-stage malaria vaccine candidate: PfRipr5 formulated with human-use adjuvants induces potent growth inhibitory antibodies

10/27/2022

Frontiers in Immunology

Page [tcb_pagination_current_page] of [tcb_pagination_total_pages]

First

Last